6-KThe Wire
Sanofi files 6-K
Filed Mar 24, 2026 · 3mo ago · Accession 0001193125-26-121156
Plain English
Sanofi announced that its venglustat drug received U.S. Breakthrough Therapy designation for type 3 Gaucher disease. This is a corporate action filing and does not contain financial results.
Filing details
- Company
- Sanofi
- Ticker
- SNY
- CIK
- 1121404
- Form type
- 6-K
- Filing date
- Mar 24, 2026
- Report date
- Mar 24, 2026
- Document
- d68462d6k.htm
- Size
- 30 KB